Detalles de la búsqueda
1.
Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia.
Acta Haematol
; 127(4): 228-34, 2012.
Artículo
Inglés
| MEDLINE | ID: mdl-22508387
2.
Evaluation of long-term outcomes, cytogenetic and molecular responses with imatinib mesylate in early and late chronic-phase chronic myeloid leukemia: a report from a single institute.
Acta Haematol
; 128(4): 223-32, 2012.
Artículo
Inglés
| MEDLINE | ID: mdl-22922489
3.
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission.
BMC Blood Disord
; 10: 7, 2010 Nov 18.
Artículo
Inglés
| MEDLINE | ID: mdl-21087500
4.
Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.
Int J Hematol
; 88(2): 243-245, 2008 Sep.
Artículo
Inglés
| MEDLINE | ID: mdl-18626727
5.
Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays.
Drug Des Devel Ther
; 7: 699-710, 2013.
Artículo
Inglés
| MEDLINE | ID: mdl-23946646
6.
Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance.
Rev Bras Hematol Hemoter
; 35(2): 103-8, 2013.
Artículo
Inglés
| MEDLINE | ID: mdl-23741187
7.
Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance
Rev. bras. hematol. hemoter
; 35(2): 103-108, 2013. ilus
Artículo
Inglés
| LILACS | ID: lil-676314
Resultados
1 -
7
de 7
1
Próxima >
>>